Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Atara Biotherap
(NQ:
ATRA
)
18.61
USD
UNCHANGED
Streaming Delayed Price
Updated: 7:53 PM EST, Jan 15, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Atara Biotherap
< Previous
1
2
3
4
5
6
7
Next >
Atara Bio Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with ATA129 in Nasopharyngeal Carcinoma (NPC)
April 21, 2017
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that it has...
From
GlobeNewswire News Releases
Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American A
April 20, 2017
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic...
From
GlobeNewswire News Releases
Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer
April 03, 2017
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific...
From
GlobeNewswire News Releases
Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS)
March 17, 2017
Presentation Selected for the Emerging Science Program at the American Academy of Neurology (AAN) Annual Meeting 2017
From
GlobeNewswire News Releases
Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights
March 09, 2017
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific...
From
GlobeNewswire News Releases
Atara Bio to Present at the 35th Annual J.P. Morgan Healthcare Conference
January 04, 2017
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific...
From
GlobeNewswire News Releases
Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (
January 03, 2017
Reimbursement Discussions with Health Technology Assessment Agencies Being Conducted in Parallel
From
GlobeNewswire News Releases
Atara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129,
December 12, 2016
Plan to Review Comparability Data with FDA Prior to Initiating Phase 3 Trials
From
GlobeNewswire News Releases
Atara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016
December 03, 2016
Response Rate (RR) and 6-month Overall Survival (OS) > 70% and Safety Findings in Hematopoietic Stem Cell Transplant (HCT) Patients with Genetically Resistant CMV Infection
From
GlobeNewswire News Releases
Atara Bio Announces Third Quarter 2016 Financial Results and Recent Highlights
November 04, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific...
From
GlobeNewswire News Releases
Atara Bio's Collaborating Investigators to Present Results from Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Ann
November 03, 2016
Presentation Includes Response Rate, 6-month Overall Survival, and Safety Results in Hematopoietic Stem Cell Transplant (HCT) Patients with CMV Mutations Conferring Resistance to Antiviral Therapy
From
GlobeNewswire News Releases
Atara Bio Granted Access to Priority Medicines (PRIME) Regulatory Support for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL) for Treatment of EBV-Associated Post Transplant
October 18, 2016
PRIME, A European Medicines Agency Initiative, Provides Enhanced Scientific Guidance and Supports Accelerated Review of Investigational Therapies Addressing Unmet Medical Need
From
GlobeNewswire News Releases
Atara Bio Receives Positive Opinion from EMA on Orphan Drug Designation for Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) for Treatment of CMV Infection in Patients with Impa
October 11, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific...
From
GlobeNewswire News Releases
Atara Bio to Participate in the Morgan Stanley Global Healthcare Conference
September 08, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that Isaac...
From
GlobeNewswire News Releases
Atara Bio Announces Second Quarter 2016 Financial Results and Recent Highlights
August 08, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today reported financial...
From
GlobeNewswire News Releases
Atara Bio to Present at the Canaccord Genuity 36th Annual Growth Conference
August 04, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that...
From
GlobeNewswire News Releases
AMAG Pharmaceuticals CEO William Heiden Elected to PhRMA Board of Directors
July 18, 2016
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, chief executive officer (CEO), has been named to the Board of Directors of the Pharmaceutical Research and Manufacturers of...
From
GlobeNewswire News Releases
Atara Bio Doses First Patient in Multi-Center Expanded Access Protocol for Study of Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) in EBV-Associated Lymphomas and Lymphoprol
July 12, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced the dosing of...
From
GlobeNewswire News Releases
Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA)
June 23, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that the EMA...
From
GlobeNewswire News Releases
Atara Bio to Present at the JMP Securities Life Sciences Conference
June 15, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by...
From
GlobeNewswire News Releases
Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate
June 06, 2016
Results Presented at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
From
GlobeNewswire News Releases
Atara Bio to Present at Three Upcoming Investor Conferences
May 31, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by...
From
GlobeNewswire News Releases
UPDATE: New Abstract Links -- Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Me
May 18, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by...
From
GlobeNewswire News Releases
Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
May 18, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by...
From
GlobeNewswire News Releases
Atara Bio’s Collaborating Investigators to Present Clinical Data on EBV-CTL at 2016 American Transplant Congress
May 09, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by...
From
GlobeNewswire News Releases
Atara Bio Announces First Quarter 2016 Financial Results and Recent Highlights
May 05, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by...
From
GlobeNewswire News Releases
Atara Bio’s Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor
April 19, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by...
From
GlobeNewswire News Releases
Atara Bio to Present at the 15th Annual Needham Healthcare Conference
April 06, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific...
From
GlobeNewswire News Releases
Atara Bio Announces Participation in Two Upcoming Immuno-Oncology Conferences
March 28, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific...
From
GlobeNewswire News Releases
Atara Bio Receives EMA Orphan Drug Designation for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder
March 23, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific...
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.